Hey mate, sorry for the late reply.
I came across PBP ages ago, can't remember why it didn't catch my eye back then, but I rediscovered it a few months back.
I went back and read through the past 5 years of annual reports, which I think is a necessary task to work out PBP today. Like I said before the ADP plant was the major problem, but we've also had brands sold to Valeant, sports nutrition written off, infighting at the board level and European operations wound back.
Has PBP turned the corner or is this the boy who cried wolf where we are fooled again? Hard to say, but as best I can tell this is the simplest business structure PBP has ever had. Contract manufacturing is a simple business, but one that requires proprietary knowledge and high quality results. As I said before, it will be the core moving forward. Branded pharmaceuticals is an off-spin of contract manufacturing, and PBP has outsourced marketing and distribution, again getting back to their core competency of drug manufacturing. Weight loss remains the high margin product, but with a much cleaner product range and again working with an external party in the CSIRO to provide guidance.
We have a bit of blue sky with product trials, but I think we could see the share price double easily from here just on fundamentals over the next year or two.
Expand